Introduction
Two kb of the HOXA10 promoter was amplified by PCR and cloned into pGL3-basic vector (Promega, Madison, WI, USA). The fragment was generated by PCR from human genomic DNA (Promega) using HOXA10 5Ј regulatory region-specific primers. The primers were designed using the GenBank database (NT_079592)
.
Statistical analysis
The Student's t-test was used for statistical evaluation.
Results

HOXA10 expression in normal endometrium, kidney and in epithelial uterine and ovarian tumours
To evaluate HOXA10 expression in above-mentioned tissues, we performed immunohistochemistry. As previous reported, HOXA10 expression in normal endometrium undergoes characteristic changes through the menstrual cycle [13, 14] . Glandular expression was low in the proliferative phase ( Fig. 1A) and increased in the secretory phase (Fig. 1B) the repressor region located in Ϫ98/Ϫ82 (bs 1) and Ϫ316/Ϫ300 (bs 2) of HOXA 10 promoter (Fig. 2B) 
WT1 expression profile in normal endometrium, kidney and in epithelial uterine, ovarian tumours
We evaluated WT1 expression in normal endometrium, kidney and in gynaecologic malignancies. In proliferative endometrium, WT1 was expressed in epithelial cells (Fig. 3A) . In normal secretory endometrium, there was no glandular WT1 staining (Fig. 3B) . In normal endometrium from post-menopausal subjects and in normal kidney WT1 immunoreactivity was prominent (Fig. 3C and D) . In G1 endometrioid carcinoma, there was no WT1 staining, in contrast to G3 endometrioid carcinomas, where there was abundant WT1 expression ( Fig. 3E and F) . In serous adenocarcinoma, WT1 was also expressed, but not in mucinous adenocarcinomas (Fig 3G and H) Fig. 4 . To confirm the specificity of binding, we added 50-fold molar excess of unlabelled probe, which resulted in decreased binding (Fig. 4 lanes labelled 'C') (Fig. 4) mutated plasmid P2 drove luciferase activity to a level more than double that driven by P1 in the 293 T cell line (P Ͻ 0.0001) (Fig. 5A) (Fig. 5B) . Transient transfection, using the P1 reporter construct containing both the epithelial enhancer and the native WT1 repressor, resulted in increased normalized luciferase activity when using WT1 siRNA compared to control siRNA (P Ͻ 0.0001) (Fig. 5C) 
WT1 binds and represses the HOXA10 promoter
Discussion
HOX genes encode regulatory proteins containing a highly conserved 61-amino acid motif, the homeodomain, which enables HOX proteins to bind to DNA specifically and transcriptionally activate or repress their target genes [16, 17] . HOX genes control cell growth and differentiation during embryonic development. Aberrant regulation of many homeobox genes has been demonstrated in a wide variety of tumours including haematologic, gynaecologic and breast malignancies [12, [18] [19] [20] [27] . Similarly, alternative splicing of WT1 mRNA can lead to Frasier syndrome, manifestations of which include male pseudohermaphroditism [28, 29] . Failure to repress the expression of HOX genes required for female reproductive tract development would be expected to lead to anomalies in males and females. WT1 is highly expressed in the genitourinary tract during embryogenesis, however is down-regulated in many of these tissues in the adult [30, 31] 
